TY - JOUR T1 - Cognitive Practice Effects Delay Diagnosis; Implications for Clinical Trials JF - medRxiv DO - 10.1101/2020.11.03.20224808 SP - 2020.11.03.20224808 AU - Mark Sanderson-Cimino AU - Jeremy A. Elman AU - Xin M. Tu AU - Alden L. Gross AU - Matthew S. Panizzon AU - Daniel E. Gustavson AU - Mark W. Bondi AU - Emily C. Edmonds AU - Graham M.L. Eglit AU - Joel S. Eppig AU - Carol E. Franz AU - Amy J. Jak AU - Michael J. Lyons AU - Kelsey R. Thomas AU - McKenna E. Williams AU - William S. Kremen AU - Alzheimer’s Disease Neuroimaging Initiative Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/05/2020.11.03.20224808.abstract N2 - Objective Practice effects on cognitive tests obscure decline, thereby delaying detection of mild cognitive impairment (MCI). This reduces opportunities for slowing Alzheimer’s disease progression and can hinder clinical trials. Using a novel method, we assessed the ability of practice-effect-adjusted diagnoses to detect MCI earlier, and tested the validity of these diagnoses based on AD biomarkers.Methods Of 889 Alzheimer’s Disease Neuroimaging Initiative participants who were cognitively normal (CN) at baseline, 722 returned at 1-year-follow-up (mean age=74.9±6.8). Practice effects were calculated by comparing returnee scores at follow-up to demographically-matched individuals who had only taken the tests once, with an additional adjustment for attrition effects. Practice effects for each test were subtracted from follow-up scores. The lower scores put additional individuals below the impairment threshold for MCI. CSF amyloid-beta, phosphorylated tau, and total tau were measured at baseline and used for criterion validation.Results Practice-effect-adjusted scores increased MCI incidence by 26% (p<.001). Adjustment increased proportions of amyloid-positive MCI cases (+20%) and reduced proportions of amyloid-positive CNs (−6%) (ps<.007). With the increased MCI base rate, adjustment for practice effects would reduce the sample size needed for detecting significant drug treatment effects by an average of 21%, which we demonstrate would result in multi-million-dollar savings in a clinical trial.Interpretation Adjusting for practice effects on cognitive testing leads to earlier detection of MCI. When MCI is an outcome, this reduces recruitment needed for clinical trials, study duration, staff and participant burden, and can dramatically lower costs. Importantly, biomarker evidence also indicates improved diagnostic accuracy.Competing Interest StatementDr. Bondi receives royalties from Oxford University Press. All other authors declare no competing interests. Funding StatementThe study was supported by grants from the U.S. National institute on Aging (MSC: F31AG064834, WSK, CEF, MJL: R01 AG050595, CEF, WSK: P01 AG055367; WSK, R01 AG022381, AG054002, AG060470; CEF, R01 AG059329; ALG: K01 AG050699; MWB: R01 AG049810) and the National Center for Advancing Translational Sciences (JAE: KL2 TR001444). The Center for Stress and Mental Health in the Veterans Affairs San Diego Healthcare System also provided support for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). This is a publicly available, de-identified data. This project was completed in accordance with ADNI data safety guidelines (http://adni.loni.usc.edu/data-samples/access-data/).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used by this project are from the Alzheimer's Disease Neuroimaging Initiative (ADNI). For access to this data, please see their data use agreement procedures: http://adni.loni.usc.edu/data-samples/access-data/ ER -